A Phase II, Open-Label, Single- Center Study to Assess the Activity of Oshadi D and Oshadi R in Combination With Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) Patients

Trial Profile

A Phase II, Open-Label, Single- Center Study to Assess the Activity of Oshadi D and Oshadi R in Combination With Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) Patients

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2016

At a glance

  • Drugs Oshadi D (Primary) ; Oshadi R (Primary) ; Cytarabine; Mitoxantrone
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Mar 2016 Planned End Date changed from 1 Jun 2017 to 1 Dec 2018 as per ClinicalTrials.gov record.
    • 28 Mar 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2018 as per ClinicalTrials.gov record.
    • 28 Mar 2016 Planned initiation date changed from 1 Jul 2015 to 1 Jan 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top